Compare · BIS vs JHB
BIS vs JHB
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and Nuveen High Income November 2021 Target Term Fund (JHB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and JHB operate in n/a (n/a), so they compete in similar markets.
- JHB carries a market cap of $525.4M.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIS
Latest JHB
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Termination and Liquidation
- SEC Form 25-NSE filed by Nuveen High Income November 2021 Target Term Fund
- Nuveen Corporate Income November 2021 Target Term Fund Announces Liquidation Details
- SEC Form N-CSRS filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form N-PX filed by Nuveen High Income November 2021 Target Term Fund
- SEC Form 3 filed by Lancellotta Amy B.R.
- Nuveen Corporate Income November 2021 Target Term Fund Announces Wind-Up Period
- SEC Form NPORT-P filed by Nuveen High Income November 2021 Target Term Fund